Introduction Polycystic ovary syndrome (PCOS) is a common disorder in women of reproductive age, with a prevalence 5–16% under different diagnostic criteria and across several ethnic groups, with exact pathogenesis still unclear ( 1 , 2 , 3
Cardiometabolic risk in polycystic ovary syndrome
Katica Bajuk Studen and Marija Pfeifer
Potential genetic polymorphisms predicting polycystic ovary syndrome
Yao Chen and Shu-ying Fang
Introduction Polycystic ovary syndrome (PCOS) is a heterogeneous and complex disorder of reproductive aged women, which usually causes reproduction and metabolism failure ( 1 , 2 ). It often presents as hyperandrogenism, hyperinsulinemia
Serum retinol-binding protein 4 levels in polycystic ovary syndrome
Shilpa Lingaiah, Laure Morin-Papunen, Terhi Piltonen, Inger Sundström-Poromaa, Elisabet Stener-Victorin, and Juha S Tapanainen
Introduction Polycystic ovary syndrome (PCOS) is the most common endocrine disorder in women of reproductive age, with an estimated prevalence of 6–15%, depending on the criteria used for diagnosis ( 1 ). It is a heterogeneous disorder with
Afamin predicts gestational diabetes in polycystic ovary syndrome patients preconceptionally
Angela Köninger, Antonella Iannaccone, Ensar Hajder, Mirjam Frank, Boerge Schmidt, Ekkehard Schleussner, Rainer Kimmig, Alexandra Gellhaus, and Hans Dieplinger
. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS) . Human Reproduction 2004 19 41 – 47 . ( https://doi.org/10.1093/humrep/deh098 ) 4 Fauser BC Tarlatzis BC Rebar RW Legro RS Balen
Polycystic ovary syndrome and risk factors for gestational diabetes
Sanna Mustaniemi, Marja Vääräsmäki, Johan G Eriksson, Mika Gissler, Hannele Laivuori, Hilkka Ijäs, Aini Bloigu, Eero Kajantie, and Laure Morin-Papunen
Introduction Gestational diabetes mellitus (GDM) and polycystic ovary syndrome (PCOS) are the most common endocrine disorders in women of reproductive age. The prevalence of GDM varies from 9% to 25% and the prevalence of PCOS varies from 5
Limitations of insulin resistance assessment in polycystic ovary syndrome
Krzysztof C Lewandowski, Justyna Płusajska, Wojciech Horzelski, Ewa Bieniek, and Andrzej Lewiński
presented in Table 2 . Table 2 Percentile distribution of insulin resistance indices in a group of 478 women with polycystic ovary syndrome. Percentiles HOMA (95% CI) IRI (Belfiore) (95% CI) QUICKI (95% CI) McAuley (95% CI
Lower sexual satisfaction in women with polycystic ovary syndrome and metabolic syndrome
Małgorzata Kałużna, Agnieszka Nomejko, Aleksandra Słowińska, Katarzyna Wachowiak-Ochmańska, Katarzyna Pikosz, Katarzyna Ziemnicka, and Marek Ruchała
Introduction Polycystic ovary syndrome (PCOS) is a common condition, affecting up to 20% of reproductive-aged women ( 1 , 2 ). PCOS is associated with significant hormonal, reproductive , metabolic, and psychological concerns. PCOS is
Are patients with polycystic ovary syndrome more prone to irritable bowel syndrome?
Małgorzata Kałużna, Pola Kompf, Katarzyna Wachowiak-Ochmańska, Jerzy Moczko, Aleksandra Królczyk, Adam Janicki, Karol Szapel, Marian Grzymisławski, Marek Ruchała, and Katarzyna Ziemnicka
Introduction Polycystic ovary syndrome (PCOS) is a complex endocrinopathy characterized by chronic, low-grade inflammation with features such as clinical and/or biochemical hyperandrogenism, oligo- or anovulation and a characteristic image of
Complex diseases and co-morbidities: polycystic ovary syndrome and type 2 diabetes mellitus
Raymond J Rodgers, Jodie C Avery, Vivienne M Moore, Michael J Davies, Ricardo Azziz, Elisabet Stener-Victorin, Lisa J Moran, Sarah A Robertson, Nigel K Stepto, Robert J Norman, and Helena J Teede
Introduction Following the recent release of international guidelines for management of polycystic ovary syndrome (PCOS) ( 1 ) endorsed by 38 international organisations in 71 countries, the research, clinical and consumer PCOS communities
Metabolic and endocrine connections of 17-hydroxypregnenolone in polycystic ovary syndrome women
Sebastião Freitas de Medeiros, Cinthia Marenza Ormond, Matheus Antônio Souto de Medeiros, Nayara de Souza Santos, Camila Regis Banhara, and Márcia Marly Winck Yamamoto
Introduction After standardization of the diagnostic criteria for polycystic ovary syndrome (PCOS) the hyperandrogenemic phenotype has been found in nearly 80% of patients ( 1 , 2 ). These hyperandrogenemic patients may have their androgen
